Work

PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.1003

Authors: Melinda L. Telli, Kristin C. Jensen, Allison W. Kurian, Shaveta Vinayak, Jafi A. Lipson, Elizabeth A. Schackmann, Irene Wapnir, Robert W. Carlson, Joseph A. Sparano, Bobbie Head, Lori J. Goldstein, Barbara B. Haley, Shaker R. Dakhil, Judith Manola, James M. Ford

Institutions: Stanford University, Albert Einstein College of Medicine, Montefiore Medical Center, Fox Chase Cancer Center, The University of Texas Southwestern Medical Center, Cancer Center of Kansas

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2244093598

Cites:

Cited by: 31

Related to: 10